Sponsor Pipeline

Innovent Biologics (Suzhou) Co. Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
58
Active Trials
33
Recruiting
16
Phase 3
10
Disease Areas
8
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-15 NCT07473960
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Enrollment closed, study ongoing
2026-08-14 NCT07265258
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
Recruitment opened
2026-08-14 NCT07265258
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
date change Primary completion pushed: 2026-09-12 -> 2028-06-30
2026-08-14 NCT07265258
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
date change Completion pushed: 2027-09-04 -> 2028-12-30
2026-08-11 NCT07722494
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Recruitment opened
2026-07-30 NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
Enrollment increased: 150 -> 180 participants
2026-07-30 NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
date change Primary completion pushed: 2025-06-06 -> 2028-10-19
2026-07-30 NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
date change Completion pushed: 2026-07-31 -> 2028-10-19
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-08-14 NCT07764861 A Open-Label Phase in Participants With Multiple Myeloma Phase 2 Not Yet Recruiting
2026-08-14 NCT07765160 Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants Phase 1 Not Yet Recruiting
2026-08-10 NCT07754786 A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants… Phase 3 Not Yet Recruiting
2026-07-23 NCT07722494 IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer Phase 3 Recruiting
Active Trials by Phase
Phase 4
1
Phase 3
16
Phase 2
15
Phase 1/2
6
Phase 1
18
Not specified
2
Active Trials — top 25 of 58
NCT IDTitleConditionStatus
Phase 4
NCT07265258 A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Thyroid Eye Disease Recruiting
Phase 3
NCT06834672 Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With… Ovarian Recruiting
NCT06931028 A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 Sleep Apnea Recruiting
NCT07066098 A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously… Pancreatic Cancer Recruiting
NCT07113262 A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive… Thyroid Eye Disease Recruiting
NCT07255209 A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Adolescents With Obesity or Overweight With Weight-Related Comorbidities Recruiting
NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Overweight Recruiting
NCT07722494 IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer Colorectal Cancer Recruiting
NCT06164873 A Study of IBI362 9 mg in Chinese Adults With Obesity Obesity Active, Not Recruiting
NCT05972473 A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD Neovascular Age-related Macular Degeneration Active, Not Recruiting
NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer Non-Small Cell Lung Cancer Active, Not Recruiting
NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With… Overweight Active, Not Recruiting
NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's… Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Active, Not Recruiting
NCT05890742 A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With… MSI-H Active, Not Recruiting
NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Relapsed or Refractory Multiple Myeloma Not Yet Recruiting
NCT07754786 A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants… Atopic Dermatitis Not Yet Recruiting
NCT07473960 IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Active, Not Recruiting
Phase 2
NCT06281678 A Study of IBI363 in Subjects with Advanced Solid Malignancies Melanoma Recruiting
NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to… Melanoma Recruiting
NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity Obesity Recruiting
NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis… Metabolic Dysfunction-associated Steatohepatitis (MASH) Recruiting
NCT07399067 A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis Atopic Dermatitis Recruiting
NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe… Atopic Dermatitis Recruiting
NCT07483567 IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of… CLDN18.2 Positive Recruiting
NCT07483554 IBI343 in Combination Therapy for Advanced Malignant Solid Tumors CLDN18.2 Positive Recruiting
See all 58 active Innovent Biologics (Suzhou) Co. Ltd. trials with filters →
Disease Areas
Get alerts when Innovent Biologics (Suzhou) Co. Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free